Screening out Serum Protein Biomarkers from Both Groups of Asthma and ABPA Patients

YANG Lei,WANG Yun,JIN Meiling,SHUAI Diquan,CAI Hui,YE Ling,LI Shuiming,SHEN Bo
DOI: https://doi.org/10.3724/sp.j.1249.2022.05538
2022-01-01
Abstract:Clinical manifestations of asthma and allergic bronchopulmonary aspergillosis (ABPA) are very similar, so that they are easy to be misdiagnosed. To improve the diagnostic accuracy of these two diseases, the protein array was firstly applied for measuring serum proteins from asthma and ABPA patients,compared with normal control subjects in this study. Protein biomarkers associated to the disease processes and with diagnostic value were analyzed by bioinformatics. The multiple reaction monitoring mass spectrometry (MRM-MS) and enzyme linked immunosorbent assay (ELISA) were then used to verify the candidate biomarkers with enlarged size of samples. The diagnostic value of candidate proteins was additionally evaluated with the receiver operating characteristic (ROC) curve. Via the comparison analysis, the disease related-candidates were identified, including 7 differentially expressed proteins(DEPs) between asthma and normal groups, 15 DEPs between ABPA and normal groups, and 15 DEPs between ABPA and asthma groups. Using MRM method, SERPINF2, C6 and HABP2 proteins were showed differential expression significantly between asthma and normal groups,SERPINF2 and F10 were represented differential expression significantly between ABPA and normal control groups, and CPN2 and IGLL5 were displayed differential expression significantly between ABPA and asthma groups. Furthermore, ELISA validation data were also showed that serum CSF1 protein levels in ABPA patients were significantly lower than those in asthma patients, while TNFRSF10C levels in ABPA patients were significantly higher than those in asthma patients. ROC curve analysis revealed that the AUC of C6 were 0.9 with the sensitivity of 73.3% and the specificity of 99.9% in comparison between asthma and normal groups. The AUC of F10 was 0.871, with the sensitivity of 80.0% and the specificity of 85.7% in comparison between ABPA and normal groups. And the AUC of the combined diagnosis of CPN2 and IGLL5 was 0.867, with more sensitivity of 86.7% and the specificity of 80.0% in comparison those between ABPA and asthma groups. In conclusion, novel protein biomarkers in this study were closely related to the occurrence and development of asthma or ABPA, and might have potentials for assistant diagnostic and differential diagnosis of those two diseases in clinical application.
What problem does this paper attempt to address?